Nithin Karanth, MD
Gastroenterology · Attleboro, MANPI 1154583953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,880 of the $146,806 with a category attached, or 85.7%. AbbVie accounts for 67.4% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $41,667 and has fallen 84.6% since, to $6,437 in 2025. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $370.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$99K
- Phathom Pharmaceuticals, Inc.$23K
- Pfizer$15K
- Nestle Healthcare Nutrition Inc.$6K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$479
- Johnson & Johnson$437
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$125,88086%
- Travel & lodging$13,2169%
- Food & beverage$7,7035%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 217 | $98,937 |
| Phathom Pharmaceuticals, Inc. | 32 | $23,237 |
| Pfizer | 14 | $15,416 |
| Nestle Healthcare Nutrition Inc. | 9 | $6,426 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $479 |
| Johnson & Johnson | 20 | $437 |
| QOL Medical, LLC | 15 | $434 |
| Ardelyx, Inc. | 14 | $292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $230 |
| Sanofi | 4 | $129 |
| Bristol Myers Squibb | 5 | $122 |
| Cook Medical LLC | 1 | $90 |
| Ironwood Pharmaceuticals, Inc | 4 | $86 |
| Gilead | 5 | $86 |
| Ferring Pharmaceuticals Inc. | 4 | $80 |
| Braintree Laboratories, Inc. | 4 | $77 |
| Aimmune Therapeutics, Inc. | 2 | $56 |
| UCB, Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Redhill Biopharma Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $19 |
| Concordia Pharmaceuticals Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$146,806 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 25 | $159,839 |
| Humira(Cf) PenAdalimumab | 20 | $134,486 |
| LinzessLinaclotide | 34 | $34,301 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 480 | $29,319 |
| Mesalamine | 58 | $24,210 |
| Ursodiol | 30 | $7,143 |
| Budesonide EcBudesonide | 19 | $7,095 |
| Mesalamine DrMesalamine | 17 | $5,420 |
| Balsalazide Disodium | 23 | $4,008 |
| Omeprazole | 249 | $3,653 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 18 | $2,944 |
| Esomeprazole Magnesium | 12 | $2,232 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 12 | $1,841 |
| Pantoprazole Sodium | 122 | $1,532 |
| Alosetron Hcl | 12 | $1,423 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $98,937 | $194,14059 claims |
| Braintree Laboratories, Inc.Sutab | $77 | $2,94418 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $479 | $1,84112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Other gastroenterology in Attleboro
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Razvan ArsenescuMedford$385K
- Steven FineFramingham$259K
- Tyler BerzinBoston$215K
- Khaldoon KhirfanBurlington$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.